Background and aims: The optimal mesalazine dosing strategy for ulcerative colitis (UC) continues to evolve. The current study aimed to explore whether documenting drug use could prompt changes in prescribing habits. Methods: In a multicenter, prospective, observational study, outpatients with active or quiescent UC were enrolled if they were receiving, or were planned to receive, sustained release mesalazine microgranules (Pentasa®). Clinical and prescribing data were collected at study entry, after 2 and 8 weeks. Physician-reported influences on prescribing decisions were recorded at study entry. Results: 360 patients were analyzed (203 active UC, 157 remission). Prior to study entry, the range of oral mesalazine doses was 0.50-6.00 g/day in active UC patients, and 0.50-4.00 g/day for patients in remission. These changed to 1.50-5.00 g/day and 1.00-4.00 g/day, respectively, at study entry with little change thereafter. Use of a single daily mesalazine dose increased from 16.7% to 58.0% of active cases during the study, and from 5.9% to 46.8% in remission cases. Gastroenterologists reported that their basis for prescription decision-making was most frequently medical experience (80.8%), followed by guidelines (67.2%), further education or colleagues' recommendations (50.0%) and current study results (20.0%). A v a i l a b l e o n l i n e a t w w w . s c i e n c e d i r e c t . c o m
Introduction
Ulcerative colitis (UC) is a chronic condition that necessitates extensive medical care and long-term medication. Although treatment guidelines for UC exist, [1] [2] [3] evidence regarding the extent to which these guidelines are applied in clinical practice is mixed. 4, 5 Treatment of UC with the aminosalicylate mesalazine is a long-established practice, but the optimal dosing strategy for its use has continued to evolve. The recent European Crohn's and Colitis Organisation (ECCO) consensus on the management of UC recommended that active left-sided UC of mild to moderate severity should first be treated with a combination of oral and topical mesalazine at a minimum dose of 2.00 g/day, which is considered more effective than topical or oral treatment alone. 3 The ECCO consensus recommended mesalazine suppositories (1.00 g/day) with oral mesalazine or steroids for mild-to-moderately active proctitis, and a combination oral mesalazine (N 2.00 g/day) with topical mesalazine for mild-to-moderate active extensive UC. For patients in remission, the consensus advises a minimum mesalazine dose of 1.00 g/day for oral therapy or 3.0 g/week for rectal therapy. 3 In terms of dosing frequency, use of once-daily dosing of mesalazine has been explored with the aim of improving adherence and thus avoiding impaired therapeutic efficacy. A series of controlled trials in active UC [6] [7] [8] [9] and quiescent UC [10] [11] [12] [13] [14] [15] [16] has demonstrated that once-daily dosing of mesalazine offers at least equivalent efficacy and safety to conventional multiple dosing regimens. 17 The systemic pharmacokinetic and pharmacodynamic characteristics of mesalazine are less relevant than for other drugs since it acts topically i.e. through luminal contact between mesalazine and the mucosal cell. A model comparing the intestinal concentrations of mesalazine after single and multiple dosing under different physiological conditions found that the predicted maximum and average concentrations in the total colon and in individual colonic segments differed by less than 10% between dosing regimens. 18 Importantly, once-daily mesalazine does not accumulate in plasma over time during ongoing treatment. 19 Thus, the clinical imperative for once-daily dosing is not contraindicated by pharmacokinetic or pharmacodynamic findings. Shortly prior to the current study, or during it, three randomized trials 8, 9, 20 and several review articles [21] [22] [23] [24] [25] were published supporting the use of once-daily mesalazine versus multiple daily doses in UC.
In the current study, the pattern of mesalazine prescribing in active and quiescent UC was selected as the basis for assessing a strategy to improve adherence to guidelines and introduction of evidence-based treatment into daily clinical practice. Mesalazine prescribing was documented over an eight-week observation period for each patient to determine how the drug was being prescribed routinely compared to recent guidelines and trial results, and to explore whether the simple process of documenting drug use could prompt changes in prescribing habits. 
Patients
All patients older than 18 years with a confirmed diagnosis of active UC or UC in remission based on typical clinical, endoscopical and histological findings were eligible for inclusion if they were currently receiving, or were planned to receive, treatment with sustained release mesalazine microgranules (Pentasa®, Ferring Arzneimittel GmbH, Kiel, Germany). Candidates were excluded if they had known intolerability to mesalazine or if full communication with the patient was not possible.
Evaluation
All patients were followed for 8 weeks. At study entry, the following data were recorded: patient demographics, date of first symptoms and first diagnosis of UC, current status (acute/remission), details of current acute flare-up (start date, type and dose of medication during remission prior to current flare-up) or current remission period (start data, type and dose of medication at start of remission), date of last endoscopy and findings (location of UC), abbreviated e126 W. Kruis et al.
Ulcerative Colitic Disease Activity Index (UC-DAI) score 26 based on clinical signs without endoscopy, quality of life using the EuroQoL instrument 16 and medication at study entry (type and dose). The UC-DAI assessed blood in the stool, frequency of stools, endoscopic evaluation of mucosal appearance (if performed), and overall physician assessment, with each item scored from 0 to 3 with higher scores indicating more severe disease. Endoscopy was not a requirement in this non-interventional, observational study. The validated EuroQoL instrument 16 comprises five areas: mobility, self-care (ability to dress and wash), general activities (work, study, housework, family activities or leisure time activities), pain/physical difficulty, and anxiety/depression, each scored from 1 to 3 with higher scores indicating greater severity of problems. Clinical assessments were repeated after 2 weeks and at the end of the observation period (week 8), including UC-DAI, quality of life (at week 8 only) and adverse events. The dose and frequency of mesalazine therapy was recorded at week 8.
The investigator's basis for prescription decision-making in each case was recorded at study entry (medical experience, medical education/colleague recommendations, guidelines or latest trial results); more than one response was possible. Investigators were also asked to respond to the question: 'Is therapy with few daily doses of mesalazine important for this patient?'
Data collection and analysis
Participating gastroenterologists completed questionnaires that were analyzed by an independent institution (IAS Institut für Angewandte Statistik, Dr. Joerg Schnitker GmbH, Bielefeld, Germany). All data are presented descriptively. Values are shown as mean (SD) or median (range).
Results

Patient population
In total, 366 patients were recruited to the study. Six patients were excluded because they were not receiving mesalazine therapy or withdrew consent, such that the study population comprised 360 patients (Table 1) . Endoscopic confirmation of the UC diagnosis was obtained in 95.0% of patients. Median age was 43 years (14-83 years), and 177 were female (49.2%). UC was active in 203 patients (56.4%) and in remission in 157 patients (43.6%). In 72 of the patients with active UC (35.5%), the current episode was the first the patient had experienced, while the remaining 131 patients had relapsing disease. Five patients discontinued the study prematurely: four patients with acute UC (two due to adverse events, two due to non-compliance) and one patient with UC in remission (adverse events and non-compliance).
Mesalazine therapy 3.2.1. Active disease
In the subpopulation of patients with active UC, 53/203 (26.1%) had previously received oral mesalazine at a median (range) dose of 2.00 (0.50-6.00) g/day and 18 patients (8.9%) had previously received rectal mesalazine at a median dose of 1.00 (0.25-4.00) g/day. At study entry, 142/203 (70.0%) of the patients with active disease received 9.0 (0-121) e127 The effect of third-party reporting in ulcerative colitis only oral mesalazine and 61 (30.0%) were given mesalazine both orally and rectally. The median (range) total dose at study entry was 3.00 (1.50-14.00) g/day, with little change thereafter ( Table 2) . During the eight-month duration of the study, the proportion of patients with active UC who received a single daily dose of mesalazine increased from 16.7% to 58.0%, while use of divided daily dosing decreased correspondingly (Fig. 1a) .
Maintenance therapy
Among the 157 patients in remission, 146 patients (93.0%) were receiving treatment prior to study entry. Twenty-three patients (14.6%) were under steroid therapy and 19 (12.1%) were given immunosuppressants. One hundred and thirtynine (139/157, 88.5%) were receiving oral mesalazine at a median dose of 2.00 (range 0.50-4.00) g/day, while 26 (16.6%) were receiving mesalazine rectally at a median dose of 1.00 (range 0.25-4.00) g/day. Overall, the median total mesalazine dose at study entry was 2.00 g (range 1.00-4.00 g), with 138/ 157 (87.9%) receiving oral mesalazine and 19/157 (12.1%) given orally and rectally administered mesalazine (Table 2) . Dosing remained stable from study entry to the end of the observation period (week 8) ( Table 2) . Similar to the patients with active UC, the use of single daily mesalazine dosing for maintenance therapy become more frequent during the eight-month study, increasing from 5.9% to 46.8% (Fig. 1b). 
Clinical status
The mean (SD) UC-DAI score in the subpopulation with active UC decreased from 5.72 (1.77) at study entry to 2.74 (2.01) at 2 weeks and 1.50 (1.89) at the end of the eight-week observation period (p b 0.0001 versus study entry). For patients in clinical remission, mean (SD) values were 1.63 (1.63) at study entry, 1.0 (1.41) at 2 weeks, and 0.76 (1.17) at 8 weeks (pb 0.0001 versus study entry). Significantly superior UC-DAI scores at the end of the observation period versus study entry were observed for both the active UC and clinical remission groups within the subpopulations receiving single or multiple mesalazine dosing (Table 3 ). There were no significant differences in UC-DAI score, or in change of score, between patients receiving single or multiple mesalazine dosing. The mean EuroQoL score showed a mean (SD) improvement of 16.7 (17.2)% for patients with active UC overall. EuroQoL scores were significantly higher at the end of follow-up versus study entry in the active UC group overall (p b 0.0001) and in the subpopulations receiving single or multiple dosing (Table 3 ). In total, 70.6% (150/201) patients with active UC reported an improvement in their quality of life. EuroQoL score also improved significantly in the remission group from study entry to the end of the observation period both overall (p b 0.0001) and in the single-dosing and multipledosing populations (Table 3) .
Physician attitudes
In the 360 cases analyzed, gastroenterologists reported that their basis for prescription decision-making was most frequently 'medical experience' (80.8%, n = 291), followed by guidelines (67.2%, n = 242), further education or colleagues' recommendations (50.0%, n = 180) and current study results (20.0%, n = 72). In the 72 cases for which gastroenterologists responded that they align their prescribing with trial results, a single daily dose of mesalazine was prescribed in 93% compared to 68% of those who did not state that trial results influence their prescribing. More gastroenterologists agreed that few daily doses of mesalazine were important for maintaining remission (82%) than for treatment of active UC (65%).
Discussion
In this analysis of routine clinical practice in gastroenterology centers in Germany, we observed a change in mesalazine prescribing for UC during an eight-week observation period after documentation of dosing regimens was started. Although mesalazine regimens were not greatly different from current ECCO guidelines 3 prior to study entry, by the end of the study period adherence to recommendations was virtually complete. Additionally, use of once-daily dosing increased markedly during the observation period, in line with evidence that a single daily dose is at least as efficacious in UC as multiple dosing. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Although this was an observational study, these findings suggest that the simple process of external reporting of drug prescribing may help to influence physician decision-making positively.
Prior to study entry, a wide range of mesalazine doses was prescribed in patients with either active UC (0.50-6.00 g/day) or quiescent UC (0.50-4.00 g/day). When mesalazine dosing was first documented at study entry, however, the minimum Table 3 Clinical status at study entry and at the end of the eight-week observation period. All differences between study entry and the end of the observation period, and between the single dosing and multiple dosing groups. The effect of third-party reporting in ulcerative colitis oral dose increased to 1.50 g/day, closer to ECCO recommendations, and no patient in remission received less than the recommended oral minimum dose of 1.00 g/day.
3 By the end of the eight-week observation period, the minimum recommended dose was also being given to all patients in the active UC group. This increase in dosing was accompanied by a remarkable increase in the proportion of patients in both the active and remission groups who received once-daily dosing, in line with clinical trial results available to gastroenterologists at that time. 8, 9, 20 Attempts to influence physicians' prescribing habits have frequently involved more elaborate change-management measures such as structured improvement strategies than the simple written documentation employed here. These interventions have included chart audits with feedback, clinical decision support tools and prescribing prompts. A Cochrane analysis found that audit and feedback processes typically had only a small to moderate effect, and even this was achieved only using higher-intensity approaches, 27 while another review which analyzed interventions that aimed to improve antibiotic prescribing practices in ambulatory care concluded that no single intervention can be recommended for all behaviors. 28 It has generally been concluded that such complex activities achieve only a small to moderate effect and the benefits are unclear, 28, 29 raising questions about whether substantial investment of resources to change doctors' behavior is justified. Less attention has been paid to the impact of simple practice systems or organizational support 30 such as the prescribing documentation undertaken in our study. Encouragingly, a registry similar to our own but in the field of cardiology was associated with substantial improvements in adherence to guidelinerecommended therapies. 31 Very recently, a registry for active Crohn's Disease patients with complex disease, all of whom were suitable candidates for immunosuppressive therapy according to ECCO guidelines, demonstrated an increase of 33.9% in the use of immunosuppressants during the 24 months' duration of the reporting period, which was associated with clinical improvements of 19.1%. 32 There are several potential limitations of this study that preclude broad generalization of the results to other settings. First, the study involved only ambulatory patients with predominantly mild to moderate UC and findings are not necessarily applicable to inflammatory bowel disease in general. Second, the study included only gastroenterologists, and the results may not be generalizable to all physicians. Indeed, even within gastroenterology there are likely to be differences in response, with a previous study reporting closer adherence to the ECCO consensus on UC treatment among gastroenterologists who specialized in inflammatory bowel disease compared to general gastroenterologists. 5 However, by including a large number of centers (107), albeit with a small average number of patients per center, we believe the study offers a broad representation of non-specialist prescribing patterns. The current study did not collect data on physician expertise, such as number of years in practice or continuing medical education in inflammatory bowel disease, but the fact that the majority of responders stated that they based prescribing decisions on their own clinical experience is consistent with a relatively specialized group of doctors.
In conclusion, it seems that the simple measure of reporting drug regimens to a third party may be associated with improved adherence to prescribing guidelines and the current evidence base. Written documentation and reporting of drug therapy and dosing schedules should be considered fundamental to the treatment of patients with chronic, complex diseases such as UC.
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